← Leaderboards
Yun Wu
State University Of New York At Buffalo
$3,163,825
Attributed
$6,215,339
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,215,339 · 6
By mechanism
R01$3,075,394 · 1
R21$1,859,999 · 4
R33$1,279,946 · 1
Top collaborators
- Grace Dy6 shared
- Chong Cheng4 shared
- Fumito Ito4 shared
- Qiaoqiang Gan3 shared
- Kate W Rittenhouse-Olson2 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Chong Cheng$2,440,190
- Robert M Straubinger$4,875,752
- Wen Wee Ma$737,204
- Chris Scott$539,205
- Laertis Ikonomou$5,222,488
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of LungSerumCohortEarly DiagnosisMicrornasNon-Small-Cell Lung CarcinomaSamplingCellsPerformanceMonitorCancer PatientHigh RiskSensitivity And SpecificityDiagnosticBiological MarkersExosomeScreeningLiquid BiopsyBaseCancer BiomarkersProteinsTechnologyDesign
Grant awards (17)
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$1,236,637
R01 · FY2025 · CA · contact PI
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$615,852
R01 · FY2024 · CA · contact PI
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$630,231
R01 · FY2023 · CA · contact PI
Exosomal Thomsen-Friedenreich glycoantigen as a new biomarker for lung cancer screening and early detection$219,559
R21 · FY2023 · CA · contact PI
Lung Cancer Early Detection and Immunotherapy Response Prediction and Monitoring with an Exo-PROS Liquid Biopsy Assay$592,674
R01 · FY2022 · CA · contact PI
Exosomal Thomsen-Friedenreich glycoantigen as a new biomarker for lung cancer screening and early detection$207,953
R21 · FY2022 · CA · contact PI
Zwitterionic Dendrimer-modified PEG for Protein Conjugation$196,990
R21 · FY2022 · EB
Zwitterionic Dendrimer-modified PEG for Protein Conjugation$236,912
R21 · FY2021 · EB
Exosome-Protein-microRNA-OneStop (Exo-PROS) biosensor: a new liquid biopsy for cancer screening and early detection$206,392
R21 · FY2021 · CA · contact PI
Exosome-Protein-microRNA-OneStop (Exo-PROS) biosensor: a new liquid biopsy for cancer screening and early detection$175,266
R21 · FY2020 · CA · contact PI
Exosome-Protein-microRNA-OneStop (Exo-PROS) biosensor: a new liquid biopsy for cancer screening and early detection$183,769
R21 · FY2019 · CA · contact PI
Synthetic Biodegradable Zwitterionic Polymers$236,399
R21 · FY2018 · EB
Noninvasive detection of circulating RNAs for lung cancer early detection and prognosis$78,787
R33 · FY2018 · CA · contact PI
Noninvasive detection of circulating RNAs for lung cancer early detection and prognosis$391,724
R33 · FY2017 · CA · contact PI
Synthetic Biodegradable Zwitterionic Polymers$196,759
R21 · FY2017 · EB
Noninvasive detection of circulating RNAs for lung cancer early detection and prognosis$397,931
R33 · FY2016 · CA · contact PI
Noninvasive detection of circulating RNAs for lung cancer early detection and prognosis$411,504
R33 · FY2015 · CA · contact PI